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Summary: CDC recommends that healthcare providers consider not only Ebola virus disease (EVD), but 
also other much more likely infectious diseases, including malaria, when evaluating ill travelers from 
Liberia to the United States. Signs and symptoms of EVD are non-specific and overlap with many other 
more prevalent infectious diseases in West Africa. For any patient returning from West Africa and 
presenting with non-specific signs and symptoms consistent with EVD, providers should use clinical 
judgment, taking into account the patient’s epidemiological history for management, diagnostic testing, 
and treatment and coordinate healthcare as needed with the state or local health department to ensure 
that these patients get appropriate care without delay. The rapid identification of the cause of an acute 
illness in a Person Under Investigation (PUI) enables rapid treatment and resolution of symptoms.   
 
Background 
Travelers from Liberia are at extremely low risk of exposure to Ebola virus at this time. For more than two 
months, there have been no cases of Ebola virus disease in Liberia. On May 9, 2015, the World Health 
Organization (WHO) declared the end of the EVD outbreak in Liberia after 42 days (two incubation 
periods) had passed since the last EVD patient was buried. It has been more than three months since the 
last case in the border regions between Liberia, Sierra Leone, and Guinea.  
 
CDC changed the country classification for Liberia on May 13, 2015, to a country with former widespread 
Ebola virus transmission and current, established control measures. CDC and other international partners 
continue to support Liberia and neighboring countries in protecting their borders through training and 
technical assistance. Border officials in Liberia are trained to screen and identify persons with symptoms 
consistent with EVD and to act quickly and safely to prevent further movement or transmission, including 
isolating sick travelers and linking them to care. Public health officials in border communities are trained 
to coordinate contact investigations with counterparts across the border.    
 
Liberia now has a stronger surveillance and response system in place for suspected EVD cases, and the 
country remains vigilant in its efforts to stay at zero cases of EVD. Liberia is prepared to handle future 
EVD cases, should they arise, through: 
• Effective surveillance  
• Integrated laboratory testing capacity  
• Sustained capacity to rapidly triage, isolate, treat, and manage suspect EVD cases 
• Cross-border communication, screening, investigation, and information sharing 
• Active and on-going dead body swabbing 
• A prevention program to reduce the potential risk of sexual transmission of Ebola virus from 
survivors to susceptible partners 
 
Recommendations 
As of May 13, 2015, patients who have only traveled to Liberia in the previous 21 days are in the low (but 
not zero) risk category for EVD, and should be evaluated for the possibility of other illnesses, based on a 
complete travel, exposure and health history. The signs and symptoms of Ebola virus disease are non-
specific, both in the early and advanced clinical course. Because EVD is very unlikely, especially in 
persons without direct contact with the blood or body fluids of a symptomatic EVD patient or direct contact 
with the body of a person who died of EVD, other more common conditions should be considered. 
  Because no cases of EVD among travelers with low (but not zero) risk of exposure who have 
been in a country with former widespread transmission in the previous 21 days have been 
documented, other more common acute conditions consistent with the signs and symptoms 
should be considered and placed higher on the list of differential diagnoses, as appropriate, and 
diagnostic testing conducted to confirm the diagnosis.     
 Travelers with low (but not zero) risk of Ebola virus exposure returning to the United States from 
Ebola affected countries over the past year, who had symptoms suggestive of Ebola, most often 
had malaria or respiratory infections. 
 
Common acute syndromes for which PUIs have presented for evaluation have included the following: 
 
1. Acute febrile illnesses without localizing signs or symptoms. These can be manifested with or 
without localizing signs by acute fever (definition ≥ 100.4 degrees Fahrenheit for PUIs), constantly 
elevated temperature or intermittent fever, subjective fever, and chills. Because the causes of fever 
among PUIs can be systemic, bacterial, viral, or parasitic, appropriate tests for these causes should 
be used to establish an alternative diagnosis.   
 
2. Acute upper and lower tract respiratory illnesses. These can be manifested with or without 
fever by sneezing, nasal congestion or stuffiness, nasal discharge, sore throat, hoarseness, eye 
burning or tearing, cough, malaise, muscle aches, and headache. Because the causes of the 
common cold, sinusitis, pharyngitis, bronchitis, and pneumonia can be bacterial or viral, appropriate 
tests for these conditions should be used to establish an alternative diagnosis.   
 
3. Acute gastrointestinal (GI) illnesses. These can be manifested with or without fever by diarrhea, 
nausea, vomiting, abdominal pain, abdominal cramps, headaches, and rash. Because the causes of 
acute GI illness are likely to be due to enteric pathogens, hydration and empiric treatment should be 
considered, taking into account travel-associated etiologies. GI symptoms may also be associated 
with respiratory or systemic infections.    
 
Rapid tests for malaria, influenza, respiratory, and gastrointestinal pathogens are helpful. Proper 
interpretation of test results is needed as these rapid tests may not have the sensitivity or specificity 
necessary to rule out a pathogen. Molecular assays have much higher sensitivity than rapid screening 
tests.  
 
For travelers from Liberia, with signs and symptoms consistent with EVD, healthcare providers should: 
 
• Place the patient in a private room with a private bathroom if he or she presents with signs 
and symptoms consistent with EVD; patient can be removed from isolation after the risk 
assessment is conducted and EVD is determined not to be the differential diagnosis 
• Follow routine standard hospital infection control practices/protocols based on symptom 
presentation 
• Conduct a thorough travel, Ebola virus exposure, and health history, including vaccination 
and prophylaxis compliance for other infectious diseases; diagnostic testing and treatment 
should be based on clinical judgment, taking into account  the patient’s EVD risk assessment 
• Evaluate the patient using clinical guidance and case definitions provided by CDC 
• Follow routine standard hospital infection control practices/protocols for use of patient care 
and other medical equipment, medical procedures, environmental infection control, and 
laboratory testing 
• Investigate other potential causes of the patient’s signs and symptoms without delay in 
patient care  
 
For any patient returning from West Africa and presenting with non-specific signs and symptoms 
consistent with EVD, providers should use clinical judgment, taking into account the patient’s 
epidemiological history for management, diagnostic testing, and treatment. The rapid identification of the 
cause of an acute illness in a PUI enables rapid treatment and resolution of symptoms.   
 
Note about Lassa fever: Healthcare providers may be concerned about a recent report of Lassa Fever, 
another viral hemorrhagic fever illness, in the US. However, Lassa fever is much less likely to be fatal 
than EVD, and there has never been person-to-person transmission of Lassa fever documented in the 
United States. Although Lassa fever is a viral hemorrhagic fever, the disease is different from EVD, which 
is responsible for the current outbreak in West Africa.  Lassa fever has an estimated 1 percent death rate 
while that for EVD has been as high as 70 percent. 
 
For more information:  
• For more information on Ebola, see http://www.cdc.gov/vhf/ebola/. 
• For more information on viral hemorrhagic fevers, see http://www.cdc.gov/vhf/virus-
families/index.html. 
• For more information on Lassa fever, see http://www.cdc.gov/vhf/lassa/.  
• For more information on malaria, see http://www.cdc.gov/malaria/. 
 
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
international organizations. 
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